Environmental Protection Industry Continues to Promote Pharmaceutical Environmental Issues
In recent years, with the continuous promotion of the industry of the Environmental Protection Department, major pharmaceutical companies have paid more and more attention to the company's improvement in pollution control and energy conservation and sustainable development. Environmental protection technology has undoubtedly become one of the core competitiveness of enterprise development.
At present, the raw material medicine industry is undergoing industrial restructuring, transformation and upgrading. The new GMP certification has already eliminated some of the production capacity through upgrading quality standards. Moreover, quite a number of companies, especially large enterprises, are aware of the importance of environmental protection and invest in environmental protection every year. Some raw material companies even use environmentally conscious methods to achieve environmental protection requirements.
Despite this, the pace of progress in pharmaceutical environmental protection seems difficult to keep up with the pace of social requirements. The late pharmaceutical industry expert Mr. Yu Guanwen once said with pain: The pharmaceutical industry owes too much environmental protection and invests too much.
According to the statistics of the environmental protection agencies, the total funds for the supervision and monitoring operations of the four major pollutants of the state-controlled major pollution sources in 2013 were 354 million yuan. It is expected that the relevant pollutant monitoring budget will continue to increase in 2014.
The reason why the standards and rules for the environmental regulations of the pharmaceutical sector are so complicated is that the pharmaceutical industry is one of the key industries with large chemical oxygen demand and large ammonia-nitrogen emissions among various industrial categories. The production of a raw material drug is often a few steps or even more than 10 steps of reaction, the use of several kinds of raw materials, and some even as high as 30-40; raw materials total consumption of more than 10kg/kg products, high more than 200kg/kg products.
It is understood that the Shijiazhuang Group has invested more than 500 million in environmental protection. It has launched 386 clean production projects and 196 energy-saving projects. It has annual electricity savings of 40 million kWh and reduced COD emissions by more than 2,000 tons. Federal Pharmaceuticals has invested more than 300 million yuan in environmental protection, and now it has a complete environmental protection system including a comprehensive equipment control system, a CASS (biological oxygen demand) pond, and an ammonia nitrogen treatment system.
Today's pharmaceutical environmental issues should rise to an industrial strategic height. With the improvement of pharmaceutical production standards, more products will go abroad, and environmental protection will also become an important promoter of eliminating backward production capacity and industrial upgrading in the future.
At present, the raw material medicine industry is undergoing industrial restructuring, transformation and upgrading. The new GMP certification has already eliminated some of the production capacity through upgrading quality standards. Moreover, quite a number of companies, especially large enterprises, are aware of the importance of environmental protection and invest in environmental protection every year. Some raw material companies even use environmentally conscious methods to achieve environmental protection requirements.
Despite this, the pace of progress in pharmaceutical environmental protection seems difficult to keep up with the pace of social requirements. The late pharmaceutical industry expert Mr. Yu Guanwen once said with pain: The pharmaceutical industry owes too much environmental protection and invests too much.
According to the statistics of the environmental protection agencies, the total funds for the supervision and monitoring operations of the four major pollutants of the state-controlled major pollution sources in 2013 were 354 million yuan. It is expected that the relevant pollutant monitoring budget will continue to increase in 2014.
The reason why the standards and rules for the environmental regulations of the pharmaceutical sector are so complicated is that the pharmaceutical industry is one of the key industries with large chemical oxygen demand and large ammonia-nitrogen emissions among various industrial categories. The production of a raw material drug is often a few steps or even more than 10 steps of reaction, the use of several kinds of raw materials, and some even as high as 30-40; raw materials total consumption of more than 10kg/kg products, high more than 200kg/kg products.
It is understood that the Shijiazhuang Group has invested more than 500 million in environmental protection. It has launched 386 clean production projects and 196 energy-saving projects. It has annual electricity savings of 40 million kWh and reduced COD emissions by more than 2,000 tons. Federal Pharmaceuticals has invested more than 300 million yuan in environmental protection, and now it has a complete environmental protection system including a comprehensive equipment control system, a CASS (biological oxygen demand) pond, and an ammonia nitrogen treatment system.
Today's pharmaceutical environmental issues should rise to an industrial strategic height. With the improvement of pharmaceutical production standards, more products will go abroad, and environmental protection will also become an important promoter of eliminating backward production capacity and industrial upgrading in the future.
Silicone Egg Ring
Chuangxin Rubber, Plastic & Metal Co., Ltd. , https://www.chuangxinsilicone.com